The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update

IF 20.1 1区医学 Q1 ONCOLOGY

Cancer Communications Pub Date : 2024-12-31 DOI:10.1002/cac2.12639

Feng Wang, Gong Chen, Zhen Zhang, Ying Yuan, Yi Wang, Yuan-Hong Gao, Weiqi Sheng, Zixian Wang, Xinxiang Li, Xianglin Yuan, Sanjun Cai, Li Ren, Yunpeng Liu, Jianmin Xu, Yanqiao Zhang, Houjie Liang, Xicheng Wang, Aiping Zhou, Jianming Ying, Guichao Li, Muyan Cai, Gang Ji, Taiyuan Li, Jingyu Wang, Hanguang Hu, Kejun Nan, Liuhong Wang, Suzhan Zhang, Jin Li, Rui-Hua Xu

{"title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update","authors":"Feng Wang, Gong Chen, Zhen Zhang, Ying Yuan, Yi Wang, Yuan-Hong Gao, Weiqi Sheng, Zixian Wang, Xinxiang Li, Xianglin Yuan, Sanjun Cai, Li Ren, Yunpeng Liu, Jianmin Xu, Yanqiao Zhang, Houjie Liang, Xicheng Wang, Aiping Zhou, Jianming Ying, Guichao Li, Muyan Cai, Gang Ji, Taiyuan Li, Jingyu Wang, Hanguang Hu, Kejun Nan, Liuhong Wang, Suzhan Zhang, Jin Li, Rui-Hua Xu","doi":"10.1002/cac2.12639","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>The 2024 updates of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the diagnosis and treatment of colorectal cancer emphasize standardizing cancer treatment in China, highlighting the latest advancements in evidence-based medicine, healthcare resource access, and precision medicine in oncology. These updates address disparities in epidemiological trends, clinicopathological characteristics, tumor biology, treatment approaches, and drug selection for colorectal cancer patients across diverse regions and backgrounds. Key revisions include adjustments to evidence levels for intensive treatment strategies, updates to regimens for deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) patients, proficient mismatch repair (pMMR)/ microsatellite stability (MSS) patients who have failed standard therapies, and rectal cancer patients with low recurrence risk. Additionally, recommendations for digital rectal examination and DNA polymerase epsilon (<i>POLE</i>)/ DNA polymerase delta 1 (<i>POLD1</i>) gene mutation testing have been strengthened. The 2024 CSCO Guidelines are based on both Chinese and international clinical research, as well as expert consensus, ensuring their relevance and applicability in clinical practice, while maintaining a commitment to scientific rigor, impartiality, and timely updates.</p>\n </section>\n </div>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 3","pages":"332-379"},"PeriodicalIF":20.1000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12639","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Communications","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cac2.12639","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The 2024 updates of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the diagnosis and treatment of colorectal cancer emphasize standardizing cancer treatment in China, highlighting the latest advancements in evidence-based medicine, healthcare resource access, and precision medicine in oncology. These updates address disparities in epidemiological trends, clinicopathological characteristics, tumor biology, treatment approaches, and drug selection for colorectal cancer patients across diverse regions and backgrounds. Key revisions include adjustments to evidence levels for intensive treatment strategies, updates to regimens for deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) patients, proficient mismatch repair (pMMR)/ microsatellite stability (MSS) patients who have failed standard therapies, and rectal cancer patients with low recurrence risk. Additionally, recommendations for digital rectal examination and DNA polymerase epsilon (POLE)/ DNA polymerase delta 1 (POLD1) gene mutation testing have been strengthened. The 2024 CSCO Guidelines are based on both Chinese and international clinical research, as well as expert consensus, ensuring their relevance and applicability in clinical practice, while maintaining a commitment to scientific rigor, impartiality, and timely updates.

Abstract Image

查看原文本刊更多论文

中国临床肿瘤学会（CSCO）：《结直肠癌诊断与治疗临床指南》，2024年更新。

中国临床肿瘤学会（CSCO） 2024年更新的《结直肠癌诊疗临床指南》强调规范中国的癌症治疗，突出了肿瘤领域循证医学、医疗资源可及性和精准医学的最新进展。这些更新解决了不同地区和背景的结直肠癌患者在流行病学趋势、临床病理特征、肿瘤生物学、治疗方法和药物选择方面的差异。主要的修订包括强化治疗策略的证据水平调整，缺陷错配修复(dMMR)/微卫星不稳定性高（MSI-H）患者方案的更新，标准治疗失败的熟练错配修复(pMMR)/微卫星稳定性（MSS）患者方案的更新，以及低复发风险的直肠癌患者。此外，直肠指检和DNA聚合酶epsilon (POLE)/ DNA聚合酶delta 1 （POLD1）基因突变检测的建议也得到加强。《2024 CSCO指南》基于国内外临床研究和专家共识，确保其在临床实践中的相关性和适用性，同时保持科学严谨性、公正性和及时更新的承诺。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

25.50

自引率

4.30%

发文量

153

审稿时长

4 weeks

期刊介绍： Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.